You might also like
Aadi Bioscience, Inc. is a biopharmaceutical company specializing in the development and commercialization of precision therapies for cancers driven by alterations in the mTOR pathway, a critical regulator of cell growth and cancer progression. The company’s primary product is FYARRO®, a nanoparticle albumin-bound formulation of sirolimus, which is FDA-approved for treating advanced unresectable or metastatic malignant perivascular epithelioid cell tumor (PEComa). Aadi focuses on expanding FYARRO's indications to other cancers and advancing its pipeline of precision therapies targeting genetically defined cancers.
- FYARRO® - A nanoparticle albumin-bound formulation of sirolimus, approved for treating advanced unresectable or metastatic malignant PEComa. FYARRO is the sole product currently commercialized by Aadi Bioscience and is central to its revenue generation.
| Name | Position | External Roles | Short Bio | |
|---|---|---|---|---|
Bryan Ball Executive | Chief Technical Operations Officer | None | Bryan Ball joined Aadi as Chief Quality Officer and SVP, Manufacturing Operations in August 2022, and was promoted to Chief Technical Operations Officer in March 2024. He has held senior roles at Intercept Pharmaceuticals and Immunomedics. | View Report → |
David Lennon, Ph.D. Executive | President and CEO | None | David Lennon, Ph.D. is the President and CEO of Aadi Bioscience, appointed on October 2, 2023. Previously, he was CEO of Satellite Bio and held leadership roles at Novartis, including President of Novartis Gene Therapies. | View Report → |
Scott Giacobello Executive | CFO and Treasurer | Board Member at Autobahn Therapeutics | Scott Giacobello is the CFO and Treasurer of Aadi Bioscience since November 2021. He served as interim CEO from March to October 2023. Previously, he was CFO at GW Pharmaceuticals and Chase Pharmaceuticals. | |
Emma Reeve Board | Director | Board Member at PTC Therapeutics | Emma Reeve has been a Director at Aadi since September 2021. She is recognized for her financial expertise and serves on Aadi's Audit Committee. She is also a board member at PTC Therapeutics. | |
Richard Maroun Board | Director | Partner, General Counsel at Frazier Healthcare Partners | Richard Maroun has been a Director at Aadi since August 2021. He is a Partner and General Counsel at Frazier Healthcare Partners and serves on boards of several companies funded by Frazier. |
- Given that FYARRO has penetrated most of the PEComa market with limited potential for further growth, what strategies do you have in place to drive additional revenue from this product or expand its indications?
- Can you provide more clarity on the potential challenges you might face in obtaining FDA approval for nab-Sirolimus based on the upcoming interim data from the PRECISION1 trial, and what contingency plans are in place if the data are not as expected?
- With the cash runway projected to extend into Q4 2025, how do you plan to fund operations beyond that point, especially considering the costs associated with advancing multiple clinical trials?
- How does nab-Sirolimus differentiate itself from other mTOR inhibitors in terms of clinical efficacy and safety, particularly in the endometrial and neuroendocrine tumor trials, and what gives you confidence it can outperform existing treatments?
- Given the competitive landscape and the relatively small patient populations for your targeted indications, how do you assess the long-term commercial viability of your pipeline assets, and what are your plans to overcome potential market limitations?
| Customer | Relationship | Segment | Details |
|---|---|---|---|
Customer #1 | Undisclosed major customer | All | 51% of total revenue for 2023 ; 44% of net accounts receivable in 2023. |
Customer #2 | Undisclosed major customer | All | 48% of total revenue for 2023 ; 56% of net accounts receivable in 2023. |
Customer #3 | Undisclosed major customer | All | 47% of total revenue for 2022. |
Customer #4 | Undisclosed major customer | All | 52% of total revenue for 2022. |
Customer #5 | Undisclosed major customer | All | 100% of net accounts receivable in 2022. |
Recent press releases and 8-K filings for AADI.
Aadi Bioscience Rebrands as Whitehawk Therapeutics
- Name Change & Ticker Update: The company has rebranded from Aadi Bioscience, Inc. to Whitehawk Therapeutics, Inc., with its common stock set to trade under the ticker WHWK on Nasdaq starting March 19, 2025.
- Financial Highlights: For Q4 2024, the company reported $7.2 million in quarterly revenue and $26.0 million for the full year, with cash, cash equivalents, and short-term investments at $47.2 million as of December 31, 2024.
- Strategic ADC Focus: The firm is shifting its focus to accelerate a portfolio of advanced antibody drug conjugate (ADC) therapies, leveraging in-licensed assets and advanced technology platforms, with a robust balance sheet expected to support operations into 2028.